Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgery vs Definitive Chemoradiotherapy for Resectable Cervical Esophageal Squamous Cell Carcinoma
ChiCTR2200058486Phase 3Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of paclitaxel and cisplatin in Squamous Cell Carcinoma of the Cervical Esophagus, squamous cell carcinoma of the hypopharynx and Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 5-year overall survival. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
paclitaxelcisplatin
03
Conditions
Squamous Cell Carcinoma of the Cervical Esophagussquamous cell carcinoma of the hypopharynxEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2200058486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058486.